The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2022 | The increasing role of liquid biopsies in lung cancer screening
Samreen Ahmed, FRCP, MD, University Hospitals of Leicester, Leicester, UK, describes how the use of circulating tumor DNA (ctDNA) has increased in the screening of lung cancer. Whilst liquid biopsies had a predominantly prognostic role, technological advancements and lower costs in ctDNA screening has enabled its use in detecting mutations. Earlier diagnosis of lung cancer will enable patients to be treated in a timely fashion and have better outcomes. This interview took place at the 20th Annual British Thoracic Oncology Group (BTOG) Conference 2022.
